Company intelligence / Profile preview

CY&N

Canada / United States / Multinational presence impliedcyan-nyc.com ↗

Ownership: Private
Development stage: Other

Overview

Cybin has reported positive Phase 2 data for its lead candidate CYB003, showing breakthrough efficacy with over 70% remission rates at 12 months after just two doses in major depressive disorder. The program has received FDA Breakthrough Therapy Designation and is now enrolling patients in a multinational Phase 3 trial. The company’s second asset, CYB004—a deuterated DMT compound—is being evaluated in a Phase 2 study for generalized anxiety disorder. Both programs are supported by an extensive intellectual property portfolio with more than 80 granted patents and over 220 pending applications.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculePsychedelic-based therapyDeuterated tryptamine derivativesNovel second-generation therapies based on psilocin, DMT, MDMA
Industry: Biotech

Partnerships

Multiple world-class partners and internationally recognized scientists mentioned but not named specifically

Beyond the preview

Go deeper on CY&N.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CY&N.

Explore the full profile